Friday, January 2, 2026 1/2/2026

Therapeutic Targeting a Non-Hodgkin Lymphoma Driver Using AI

Award Number: R01CA271546
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 12/16/2022
PERIOD OF PERFORMANCE END DATE: 11/30/2027

Group Awards By:

View Award Description

Therapeutic Targeting a Non-Hodgkin Lymphoma Driver Using AI - Therapeutic Targeting a Non-Hodgkin Lymphoma Driver using AI PROJECT SUMMARY Baylor College of Medicine (BCM) and Atomwise Incorporation have partnered to discover, optimize, and test inhibitors to undruggable oncoproteins using artificial intelligence (AI). Both Hodgkin lymphoma and non- Hodgkin lymphoma (NHL) are cancers that start in lymphocytes, which are part of the body’s immune system. The main difference between Hodgkin lymphoma and NHL is in the specific lymphocyte each involves: in the presence of abnormal cells called Reed-Sternberg cells, the lymphoma is classified as Hodgkin’s; otherwise, it is classified as NHL. NHL is the most common blood cancer and causes over 20,000 deaths every year in the United States. There are about 90 types of NHL, which usually develop when mutations occur within a lymphocyte. The gene MYD88 encodes myeloid differentiation primary response 88 protein, a critical universal adapter with essential functions in inflammation and immunity. Following stimulation of toll-like receptors, MYD88 transduces the signal to activate genes responsible for innate and adaptive immune responses. MYD88 is a driver oncogene that is frequently mutated in B-cell NHLs. The most frequent missense mutation is L265P, which changes leucine at position 265 to proline and accounts for ~90% of all MYD88 mutations. MYD88 L265P is found in ~90% of Waldenström macroglobulinemia (WM, a rare NHL), >50% of primary extranodal lymphomas, and ~29% of activated B-cell diffuse large B-cell lymphomas (DLBCL). WM is considered incurable. DLBCL can be cured in about 40% of the patients, but those with MYD88 L265P have poorer survival than those without. BCM collaborates with Atomwise, the inventor of the first deep learning AI technology based on neural networks and a leader in AI-assisted drug discovery, to virtually screen 2.7 million compounds. We identified scores of AI-selected compounds targeting a binding site near L265P in MYD88. We validated these hits by evaluating their inhibition of MYD88 L265P ubiquitination and xenograft tumorigenesis. One compound attenuated lymphoma growth from NHL cells with MYD88 L265P, but not that with WT MYD88. We hypothesize that adaptor oncoproteins such as MYD88 L265P can be targeted by AI. In this application, we propose two specific aims to develop drug candidates that target MYD88 L265P for NHL therapy. In Aim 1, we will use AI to virtually screen billions of compounds to discover novel drug candidates targeting a binding site near L265P in MYD88. In Aim 2, we will optimize validated hit compounds targeting MYD88 L265P. Data generated from this partnership will provide a solid scientific platform for therapeutic development targeting the oncogenic MYD88 L265P while sparing WT MYD88, which is critical for both innate and adaptive immunity. This work addresses the unmet clinical need to target MYD88 L265P directly and advances drug development against mutation-specific drivers.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $590,477 )
2026	2026	BAYLOR COLLEGE OF MEDICINE	1 BAYLOR PLZ	HOUSTON	TX	77030	HARRIS	USA	Cancer Treatment Research	000	4	12/10/2025	NON-COMPETING CONTINUATION	$590,477
														Subtotal = $590,477

Issue Date FY: 2025 ( Subtotal = $656,085 )
2025	2025	BAYLOR COLLEGE OF MEDICINE	1 BAYLOR PLZ	HOUSTON	TX	77030	HARRIS	USA	Cancer Treatment Research	001	3	5/30/2025	NON-COMPETING CONTINUATION	$65,608
2025	2025	BAYLOR COLLEGE OF MEDICINE	1 BAYLOR PLZ	HOUSTON	TX	77030	HARRIS	USA	Cancer Treatment Research	000	3	11/21/2024	NON-COMPETING CONTINUATION	$590,477
														Subtotal = $656,085

Issue Date FY: 2024 ( Subtotal = $623,283 )
2024	2024	BAYLOR COLLEGE OF MEDICINE	1 BAYLOR PLZ	HOUSTON	TX	77030	HARRIS	USA	Cancer Treatment Research	000	2	11/13/2023	NON-COMPETING CONTINUATION	$590,477
2024	2024	BAYLOR COLLEGE OF MEDICINE	1 BAYLOR PLZ	HOUSTON	TX	77030	HARRIS	USA	Cancer Treatment Research	001	2	4/22/2024	NON-COMPETING CONTINUATION	$32,806
														Subtotal = $623,283

Issue Date FY: 2023 ( Subtotal = $656,085 )
2023	2023	BAYLOR COLLEGE OF MEDICINE	1 BAYLOR PLZ	HOUSTON	TX	77030	HARRIS	USA	Cancer Treatment Research	000	1	12/16/2022	NEW	$656,085
														Subtotal = $656,085

Grand Total All Awards = $2,525,930

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Therapeutic Targeting a Non-Hodgkin Lymphoma Driver Using AI

Award Number: R01CA271546

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 12/16/2022

PERIOD OF PERFORMANCE END DATE: 11/30/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer